Loading…

IndegeneINDGN.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.

≈ A life-sciences-focused digital/commercial services firmMomentum leader 86
Mkt cap
$1.69B
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$4.71M
20-day average traded
Fwd P/E
29.5×
forward earnings
ROIC−WACC
+1.1 pp
WACC 15.9%
Hurdle
+2 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · INR₹654.95
1D+1.0%
1W+6.3%
1M+11.3%
3M+15.4%
6M+28.1%
YTD+25.8%
1Y+28.7%
ATR %3.2%
Beta0.72
52w lowhigh3.3% off high

What Indegene does

Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.

Charges fees to drugmakers for work done by its own staff and platforms, from content creation and sales-and-marketing operations to regulatory documentation, usually under multi-year contracts. The US is its largest market. It listed on the Indian stock market in 2024.

In one line: A life-sciences-focused digital/commercial services firm.

Products and services

  • Commercial/marketing services
  • Medical affairs/content services
  • Enterprise technology platforms

Customers

  • Global pharma/biotech companies

Where it sits in the supply chain

  • Pharma commercial operations…
  • Data/AI-driven marketing tech
  • Regulatory/medical content services

What could go right

  • Pharma outsourcing of commercial ops
  • AI-driven content demand

What could go wrong

  • Client (pharma) R&D budget cuts
  • Competition from large consultancies

Moat: narrow (process know-how, switching costs). Deep life-sciences domain expertise and embedded workflows create switching costs versus generic IT vendors.

Headquarters: Bengaluru, India · Founded: 1998 · Employees: 5,175

Named competitors

Indegene at a glance

Size Indegene (INDGN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.69B, the 429th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹654.95 on 18 Nov 2026.

Performance Over six months the shares gained 28.1%, against -3.0% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 35.8% over the last twelve months (peer median +6.8%); the operating margin is 12.4% (peer median 12.0%).

Valuation It trades at 29.5× forward earnings against a peer median of 21.4× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.1 points above its cost of capital (15.9% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026INDGN.NS 128Peer median 96
Six months, rebased to 100: Indegene against the median of its 20 peers (local-currency closes).

Indegene financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹41.3B₹35.1B₹28.4B₹25.9B₹23.1B
Revenue growth—+24%+10%+12%—
Gross profit₹5.11B₹8.79B₹7.72B₹6.94B₹5.81B
EBITDA₹6.83B₹6.27B₹5.38B₹5.14B₹3.99B
Net income₹4.11B₹4.01B₹4.07B₹3.37B₹2.66B
Free cash flown/a₹6.19B₹4.61B₹4.92B₹1.00B
Capital expendituren/a₹443M₹300M₹107M₹188M
Total debt₹1.57B₹1.44B₹1.02B₹4.90B₹5.03B

Quarterly statements and history in the cockpit →

Indegene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%600993CAPLIPOINT300723300357FAEMAZE688166NATCOPHARM1681ASTRAZENAGIO9989ANURAS600664301047002755ETONINDGN.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Indegene is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×80×600993CAPLIPOINT300723300357FAE688166NATCOPHARM16819989ANURAS600664301047002755ETON600420INDGN.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Indegene is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600993CAPLIPOINT3007231681ASTRAZENETONINDGN.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Indegene is the large dot.

Indegene competitors and peer comparison

Head to head with its named competitors (INDGN.NS vs IQV vs ACN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Indegene INDGN.NS$1.69B+28%+36%12%29.5×31.4%
Iqvia IQV$42.5B+50%+9%14%18.7×16.8%
Accenture ACN$134B+27%+6%15%15.5×1.7%

How Indegene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Indegene against its 20 peers (data as of 18 Nov 2026)
MeasureINDGN.NSPeer medianRank in peer set
1-month return+11.3%-3.9%3rd highest of 21
6-month return+28.1%-3.0%3rd highest of 20
Distance from 52-week high-3.3%-35.8%highest of 21
Revenue growth (TTM)+35.8%+6.8%3rd highest of 20
Operating margin12.4%12.0%10th highest of 20
Forward P/E29.5×21.4×5th most expensive of 16
Growth the price implies (Req g, 7 yrs)31.4%15.6%4th most demanding of 17
Growth delivered (Del g)+29.4%+8.7%2nd highest of 17
Hurdle (Req g minus delivered)+2.0 pp+4.5 pp9th least demanding of 17
ROIC minus cost of capital+1.1 pp-1.3 pp10th highest of 21
EV / EBITDA21.5×21.4×4th most expensive of 8
Net debt / EBITDA-1.6×-0.7×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%

Questions

Who are Indegene's main competitors?
Named competitors: IQVIA (IQV), Accenture Life Sciences (ACN), ZS Associates (private or unlisted). The cockpit's measured peer set (industry) also includes Mayinglong Pharmaceutical (600993.SS), Caplin Point Laboratories (CAPLIPOINT.NS), ApicHope Pharmaceutical (300723.SZ), Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ), Faes Farma (FAE.MC), Maze Therapeutics (MAZE).
Is Indegene expensive compared with its peers?
On forward p/e it trades at 29.5× against a peer median of 21.4×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Indegene stock performed?
Over six months to 18 Nov 2026 the shares returned +28.1% against -3.0% for the median peer; over one year +28.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.